HRT Financial’s AnaptysBio ANAB Stock Holding History

HRT Financial’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-52,500	Closed	-$2.54M	–	3733
2025 Q4	$2.54M	Buy	+52,500	New	+$2.05M	0.01%	1143

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

HRT Financial's ANAB Position: Q2 2026 in Review

HRT Financial sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 40,504 shares — an estimated $2.25M sold.

HRT Financial first reported a position in ANAB in Q2 2020 and held it in 13 quarters. The position peaked at $3.4M in Q4 2025. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

HRT Financial reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 40,504 AnaptysBio shares in Q2 2026, an estimated $2.25M.
HRT Financial first reported a position in AnaptysBio in Q2 2020 and held it in 13 quarters.
HRT Financial's AnaptysBio position peaked at $3.4M in Q4 2025.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.